Semaglutide’s effect on inflammation marker CRP in overweight or obese patients with heart disease

Among 17,604 patients with atherosclerotic cardiovascular disease and obesity, randomization to semaglutide significantly reduced major adverse cardiovascular events compared with placebo.

• The primary outcome measured was major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
• Inflammation, indicated by plasma levels of high-sensitivity C-reactive protein (hsCRP), may serve as a biomarker for cardiovascular risk in individuals with obesity and atherosclerotic cardiovascular disease.
• The SELECT trial offers an opportunity to explore the connections between hsCRP levels, obesity, weight loss, and cardiovascular outcomes in patients treated with semaglutide versus those receiving placebo.

Simplified